Circulation reports最新文献

Background: Although mitral valve repair typically leads to left atrial reverse remodeling, persistent left atrial enlargement is associated with poor prognosis. Factors contributing to postoperative left atrial enlargement remain poorly understood. Left atrial strain analysis may offer supplementary evaluation of left atrial function, complementing conventional volume-based assessments.

Methods and results: Echocardiographic data of 76 patients who underwent mitral valve repair for primary mitral regurgitation due to leaflet prolapse were retrospectively analyzed. Left atrial volume index and strain parameters were evaluated preoperatively and 1 year postoperatively. Predictors of postoperative left atrial enlargement (left atrial volume index ≥34 mL/m²) were assessed by logistic regression and receiver operating characteristic analyses. Postoperatively, left atrial volume index decreased significantly (from 64.4±23.1 to 36.6±10.5 mL/m²; P<0.01) and there was a significant decline in left atrial strain parameters. Preoperative left atrial early longitudinal strain rate was an independent predictor of postoperative left atrial enlargement (odds ratio 0.076; 95% confidence interval 0.07-0.80; P=0.032), with a receiver operating characteristic curve-derived cut-off of 0.815%/s (area under the curve 70.2%, sensitivity 81.1%, specificity 59.0%).

Conclusions: Left atrial early longitudinal strain rate is an independent predictor of postoperative left atrial enlargement following mitral valve repair, providing valuable prognostic information.

Background: Acute kidney injury (AKI) is a common and serious post-transcatheter aortic valve replacement (TAVR) complication that affects patient outcomes. Low-flow, low-gradient (LFLG) aortic stenosis (AS) and chronic kidney disease (CKD) represent a high-risk subset of patients undergoing TAVR. The objective of this study was to evaluate the prognostic impact of LFLG-AS and AKI in CKD patients undergoing TAVR.

Methods and results: A retrospective analysis was conducted on 324 patients with CKD stage G3a-5 who underwent TAVR for severe AS between August 2015 and December 2022. Patients were stratified into 4 groups according to the presence of LFLG- AS and AKI. The primary endpoint was defined as all-cause mortality or heart failure during the 2-year follow-up period. During a median period of 13 months, 46 (14%) patients reached the primary endpoint. The difference between the baseline values for renal function of the patients with AKI or without AKI was not significant. The patients without either condition who had the most favorable outcomes were those without LFLG-AS or AKI. Patients with LFLG-AS only or AKI only had intermediate outcomes. The patients with LFLG-AS and AKI showed significantly higher mortality and adverse outcomes than the other groups (log-rank P<0.001).

Conclusions: This study highlighted the severe prognostic implications of AKI for patients with LFLG-AS who undergo TAVR.

Background: Although implantable cardioverter-defibrillators (ICD) offer prognostic benefit for patients with reduced left ventricular ejection fraction (LVEF), they remain underused in Japan.

Methods and results: We analyzed 25 patients who underwent primary prevention ICD implantation. During a median follow-up of 52.6 months, no appropriate shocks occurred, but non-sustained ventricular tachycardia (NSVT) was frequently observed. Two patients underwent antitachycardia pacing. LVEF improved to >35% in nearly half of the patients.

Conclusions: Cardiac resynchronization therapy and pharmacotherapy possibly improved cardiac function. Unnecessary shock delivery programming may have also contributed to the favorable outcomes.

Background: The incidence of atrial fibrillation (AF) is high in lung cancer patients, but the clinical and prognostic significance of AF during the non-perioperative period is unknown.

Methods and results: We performed a retrospective single-center cohort study of consecutive patients diagnosed with primary lung cancer. Of the 383 patients included in this study, 27 (7.04%) developed AF during the non-perioperative period (median follow-up 1.68 years). At the baseline, the AF group had a significantly higher prevalence of age ≥70 years or older, diabetes, heart diseases, chronic kidney disease, and high C-reactive protein (CRP) (>0.6 mg/dL). Multivariate analysis using propensity scores showed that high CRP was an independent risk factor for developing AF (odds ratio 3.08; 95% confidence interval 1.17-8.06; P=0.022). Although most (81.5%) of the AF group had no or mild symptoms, the overall survival rate was significantly lower in the AF than non-AF group. Body mass index ≤25.4 kg/m² was associated with lower survival rate in the AF group, but not in the non-AF group.

Conclusions: In lung cancer patients, the incidence of AF was high during the non-perioperative period, and high CRP was an independent risk factor for developing non-perioperative AF. Although the symptoms were milder, non-perioperative AF was associated with a higher risk of all-cause mortality, and BMI had significant predictive value for mortality.

Extracorporeal membrane oxygenation (ECMO) delivers powerful mechanical circulatory support while simultaneously offering respiratory support; however, it can increase afterload and is associated with potential device-related vascular complications. To date, several randomized controlled trials have failed to demonstrate a prognostic benefit of routine use of ECMO in patients with cardiogenic shock secondary to acute myocardial infarction or in those with out-of-hospital cardiac arrest. Therefore, the routine use of ECMO is not a guideline-recommended therapeutic strategy. However, in real-world clinical practice, a considerable proportion of patients with cardiogenic shock and cardiac arrest have no other therapeutic options besides ECMO to save their life. Additionally, a combination of ECMO with other mechanical circulatory support devices, such as an intra-aortic balloon pump and percutaneous ventricular assist device, may help reduce the limitations of ECMO and improve patient outcomes. The results of ongoing randomized trials will shape our understanding of the role of ECMO itself and the combination strategies in patients with cardiogenic shock and out-of-hospital cardiac arrest.

Background: Inflammation in epicardial adipose tissue (EAT) has been hypothesized to influence heart structure and function, thereby contributing to aortic valve (AV) disease. However, it remains unclear how the biological state of EAT is related to AV hemodynamics.

Methods and results: We studied 50 patients with AV calcification who underwent elective cardiac surgery (cardiac valve surgery and/or coronary artery bypass graft). Echocardiographic data (AV area index [AVAI] and peak transvalvular AV velocity [PAVV]), were acquired before surgery. During cardiac surgery, 2 EAT samples were obtained for immunohistochemistry and the number of CD68- and CD11c-positive macrophages and osteocalcin-positive cells was counted in 6 random high-power fields (×400 magnification). PAVV, but not AVAI, was positively correlated with the number of CD11c-positive macrophages and osteocalcin-positive cells in EAT in patients with clinical AV stenosis (AS), defined as PAVV ≥2.5 m/s. On multivariate analysis adjusted for left ventricular function, the number of osteocalcin-positive cells in EAT was independently correlated with increased PAVV (β=0.42; P=0.013) and the presence of clinical AS (odds ratio per 1-unit increase 1.14; P=0.011), whereas there was no correlation between increased PAVV or the presence of clinical AS and the number of CD68- and CD11c-positive macrophages in EAT.

Conclusions: The biological activities of EAT, which are characterized mainly by osteogenic activity, are associated with AV hemodynamics and may contribute to AS progression.

Background: Chronic heart failure (CHF) affects millions worldwide, posing a significant burden on healthcare resources. For patients with HF with reduced ejection fraction (HFrEF) following a worsening event, vericiguat is a promising new treatment. In this study we evaluated the budgetary impact on Japan's health system with the introduction of vericiguat as an add-on to standard of care (SoC) for chronic HFrEF after a worsening event.

Methods and results: An economic model was developed comparing SoC to a scenario in which vericiguat is introduced as an add-on therapy over a 5-year time horizon. A literature review, medical claims data and clinical trial data were used to derive inputs. Total healthcare costs after introducing vericiguat were estimated to increase <1% over 5 years compared to the SoC scenario showing a cumulated budget impact of US$41,027,304. Increases were driven by drug and medical costs, but were partially offset by decreasing costs for hospitalizations, terminal care, and urgent HF visits. In the sensitivity analyses, the hospitalization rate had the largest effect on the overall budget impact.

Conclusions: This analysis highlighted the minimal budgetary impact of vericiguat and its potential to reduce hospitalizations in Japan. Although drug and monitoring costs increased, reductions in acute care expenses helped offset these costs. Further research is needed on long-term cost-effectiveness and real-world outcomes.

Background: Sex differences exist in atherosclerotic cardiovascular disease, partly due to the anti-atherosclerotic properties of estrogens in women. While polyvascular disease (PolyVD) exhibits worse outcomes, it is unknown whether women have an impact on cardiovascular outcomes of PolyVD.

Methods and results: We analyzed 678 coronary artery disease patients receiving PCI. PolyVD was defined as the concomitance of ischemic stroke and/or lower extremity arterial disease (LEAD). The occurrence of 3-year major adverse cardiovascular events (MACE; i.e., all-cause death + non-fatal myocardial infarction + ischemic stroke + ischemic-driven non-culprit lesion revascularization + LEAD) was compared between men and women with and without PolyVD, respectively. Women accounted for 17.8% and 21.1% of patients with and without PolyVD, respectively (P=0.34). In patients without PolyVD, women presented marginally higher on-treatment low-density lipoprotein cholesterol (LDL-C) levels (101.5 vs. 93.0 mg/dL; P=0.05). However, women exhibited a lower 3-year MACE risk (adjusted hazard ratio [HR] 0.31; 95% confidence interval [CI] 0.11-0.88; P=0.02). In patients with PolyVD, women exhibited higher LDL-C levels (103.0 vs. 82.0 mg/dL; P=0.04). Furthermore, even after adjusting clinical demographics and risk factor control, the 3-year MACE risk did not differ between males and females (adjusted HR 0.67; 95% CI 0.29-1.57; P=0.36).

Conclusions: Women without PolyVD were less likely to experience 3-year MACE, whereas cardiovascular outcomes in women with PolyVD were similar to men with PolyVD. These findings suggest a need to intensify anti-atherosclerotic management in both men and women with PolyVD.

Intravenous magnesium is commonly used in clinical practice for treating Torsade de Pointes (TdP), although supporting evidence remains limited. This scoping review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension guidelines. Four online databases were searched for relevant studies published as of November 27, 2024, but only 4 observational studies met the inclusion criteria. TdP resolved in a substantial proportion of patients treated with intravenous magnesium (78.3% [N=36/46]), although most studies lacked a control group. No serious adverse events related to magnesium were reported (0% [N=0/46]). Despite several limitations that preclude firm conclusions, intravenous magnesium appears to be a relatively safe and effective treatment for TdP. However, TdP progressed to ventricular fibrillation (VF) in 21.7% (N=10/46) of patients, underscoring the need for readiness to perform immediate electrical defibrillation during treatment. Further high-quality studies are warranted to validate these findings.